Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Imprimis Phar (IMMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Consolidated Research: 2018 Summary Expectations for FTD Companies, PRA Group, Equity Bancshares, ConforMIS, Immune Design, and Imprimis Pharmaceuticals -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FTD Companies, Inc. (NASDAQ:FTD),...

IMMY : 2.78 (-0.71%)
EQBK : 40.79 (+0.32%)
CFMS : 1.18 (-4.84%)
FTD : 2.75 (-8.03%)
PRAA : 38.85 (unch)
IMDZ : 3.50 (-1.41%)
Imprimis: 2Q Earnings Snapshot

SAN DIEGO (AP) _ Imprimis Pharmaceuticals Inc. (IMMY) on Monday reported second-quarter earnings of $2.5 million.

IMMY : 2.78 (-0.71%)
Imprimis Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Imprimis Pharmaceuticals, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern...

IMMY : 2.78 (-0.71%)
Imprimis Announces Multi-Center Clinical Trial for Dropless® TriMoxi(TM) (Triamcinolone Acetonide-Moxifloxacin for injection) Formulation in Canada

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) through its ImprimisRx ophthalmology business today announced its Canadian partner, Advanced Dosage Forms Inc., will begin enrolling patients at McGill University...

IMMY : 2.78 (-0.71%)
Imprimis Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 6, 2018

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today announced it will release second quarter 2018 financial results after the close of trading on Monday, August 6, 2018. The company will host a conference...

IMMY : 2.78 (-0.71%)
Imprimis: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Imprimis Pharmaceuticals Inc. (IMMY) on Tuesday reported a loss of $3.5 million in its first quarter.

IMMY : 2.78 (-0.71%)
Imprimis Pharmaceuticals Announces First Quarter 2018 Results

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported financial results for the first quarter 2018.

IMMY : 2.78 (-0.71%)
Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners

Surface Pharmaceuticals, Inc., an affiliated company of Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), today announced it has entered into a definitive stock purchase agreement with an affiliate of Flying...

IMMY : 2.78 (-0.71%)
Research Report Identifies Albany International, JBG SMITH Properties, Preferred Apartment Communities, National Western Life Group, Phibro Animal Health, and Imprimis Pharmaceuticals with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Albany International Corporation...

APTS : 17.32 (+1.35%)
NWLI : 319.76 (-0.36%)
IMMY : 2.78 (-0.71%)
AIN : 78.20 (-0.89%)
JBGS : 37.55 (+0.19%)
PAHC : 42.30 (-2.65%)
Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), and its ophthalmology-focused ImprimisRx division, today announced its participation and related physician presentations at the 2018 American Society of Cataract...

IMMY : 2.78 (-0.71%)
Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it has secured a patent covering the company's innovative MKO (midazolam, ketamine, and ondansetron)...

IMMY : 2.78 (-0.71%)
Analysis: Positioning to Benefit within Enbridge Energy Management, Imprimis Pharmaceuticals, Hibbett Sports, Glacier, Regis, and Fox Factory Holding -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Enbridge Energy Management...

EEQ : 11.65 (+0.60%)
HIBB : 19.90 (-3.40%)
GBCI : 44.31 (-1.60%)
IMMY : 2.78 (-0.71%)
FOXF : 71.85 (-0.35%)
RGS : 20.92 (-1.27%)
Imprimis reports 4Q loss

SAN DIEGO (AP) _ Imprimis Pharmaceuticals Inc. (IMMY) on Thursday reported a loss of $2.8 million in its fourth quarter.

IMMY : 2.78 (-0.71%)
Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the fourth quarter 2017.

IMMY : 2.78 (-0.71%)
Wired News - Imprimis Pharma Launched New Program for Custom Compounded Ophthalmic Medications

Stock Monitor: Akcea Therapeutics Post Earnings Reporting

IMMY : 2.78 (-0.71%)
AKCA : 27.98 (-3.25%)
Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company's business...

IMMY : 2.78 (-0.71%)
Imprimis Pharmaceuticals to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. EST

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release third quarter 2017 financial results after the close of trading on Tuesday,...

IMMY : 2.78 (-0.71%)
8-K: Imprimis Pharmaceuticals, Inc.

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

IMMY : 2.78 (-0.71%)
Imprimis Launches Surface Pharmaceuticals Subsidiary

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it has filed a Form 8-K with the SEC which contains a corporate presentation for its subsidiary,...

IMMY : 2.78 (-0.71%)
Today's Research Reports on Stocks to Watch: Alcobra and Imprimis Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / October 20, 2017 / Alcobra headed higher on Thursday after the company's wholly-owned subsidiary Arcturus entered into a research collaboration and worldwide license agreement...

ADHD : 1.46 (-85.10%)
IMMY : 2.78 (-0.71%)
JNJ : 142.88 (+0.63%)
AGN : 191.31 (-0.62%)

Van Meerten Stock Picks

Tesla According to Peter Lynch
Today's Barchart Chart of the Day will be the auto maker Tesla (TSLA).
TSLA +0.77
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

cmdty Insider - Ag Market Commentary

Today's Commentary

Corn futures closed the Friday session with most contracts 4 to 5 cents in the green. Nearby Dec was up 1.56% over the course of the week. A private export sale this morning was shown for 121,700 MT of 18/19 corn to unknown by the USDA. Total corn ex...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar